Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Name: Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Published: 2022
License: Public Domain

Oryzon Genomics S.A. · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

acute-myeloid-leukemia

acute myeloid leukemia, in relapse, acute myeloid leukemia refractory, acute myeloid leukemia, flt3 mut, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Related documents